Navigation Links
OncoGenex Pharmaceuticals Added to Russell Indexes
Date:6/30/2009

BOTHELL, WA, and VANCOUVER, June 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer, announced today that the Company was added to the Russell 3000(R) Index, the Russell 2000(R) Index and the Russell Microcap(R) Index at the close of market on June 26, 2009 as part of the annual reconstitution of Russell indexes.

The Russell 3000 Index measures the performance of the largest 3000 U.S. companies representing approximately 98% of the investable U.S. equity market. The Russell 3000 Index is constructed to provide a comprehensive, unbiased, and stable barometer of the broad market and is completely reconstituted annually to ensure new and growing equities are reflected.

The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity universe. The Russell 2000 Index is a subset of the Russell 3000 Index representing approximately 10% of the total market capitalization of that index. The Russell 2000 is constructed to provide a comprehensive and unbiased small-cap barometer.

The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market. It makes up less than 3% of the U.S. equity market. It includes 1000 of the smallest securities in the small-cap Russell 2000(R) Index. Russell Microcap Index is constructed to provide a comprehensive and unbiased barometer for the microcap segment trading on national exchanges, while excluding lesser-regulated OTC bulletin board securities and pink-sheet stocks due to their failure to meet national exchange listing requirements.

The Russell 2000 and Microcap Indexes are reconstituted annually to ensure larger stocks do not distort performance and characteristics of the
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Pharmaceuticals Files Shelf Registration Statement
2. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
4. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
5. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
6. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
7. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
8. OncoGenex Reports First Quarter Financial Results
9. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
10. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
11. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013 As a leading provider ... announces the release of their infographic - " ... , MeMD's goal was to leverage an information ... 2.0, Health 3.0 and mHealth.The infographic features a ... care and the fitness industry in unimaginable ways; ...
(Date:6/18/2013)... Minneapolis, MN (PRWEB) June 18, 2013 ... the Saniclave 200 prevent the dangers of ... confusing features, like knobs, analog pressure gauges, hot surfaces ... older autoclave, or a new, modern autoclave, Revolutionary Science ... use fresh water. Older autoclave designs will recycle ...
(Date:6/18/2013)... DC (PRWEB) June 18, 2013 On ... Services (CMS) released a final decision memorandum concluding ... to guide subsequent management of anti-tumor strategy, and ... collection. The National Oncological PET Registry (NOPR) was developed ... the first projects under the Coverage with Evidence Development ...
(Date:6/17/2013)... , June 17, 2013  KaloBios Pharmaceuticals, Inc. (Nasdaq: ... Donald R. Joseph as Chief Legal Officer.  ... biopharmaceutical industry experience and has worked in both public ... non-profit organizations. (Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO ) ... record as a general counsel and senior executive and ...
Breaking Biology Technology:MeMD, Inc Releases Infographic Featuring the Top Eight Technologies that are Revolutionizing Health and Fitness Today 2How to Autoclave: Why the User Friendliness of the Saniclave 200 is So Important Today 2WMIS Welcomes CMS Decision: Expanding Coverage for FDG-PET and Ending NOPR Data 2WMIS Welcomes CMS Decision: Expanding Coverage for FDG-PET and Ending NOPR Data 3KaloBios Appoints Donald R. Joseph as Chief Legal Officer 2KaloBios Appoints Donald R. Joseph as Chief Legal Officer 3KaloBios Appoints Donald R. Joseph as Chief Legal Officer 4
... 2012 All Global , the ... of patient access offers, building off developments in technology ... traditional research methods in providing greater access to patient ... these new offers comes in the area of diabetes, ...
... March 22, 2012 , Prophecy,s pre-hire ... Elsevier Performance Manager   ... more than 1,300 healthcare organizations, today announced its collaboration ... nurse assessment and competency evaluation.  Elsevier will distribute Prophecy,s ...
... BELGRADE, Mont., March 22, 2012 Bacterin International Holdings, Inc. ... development of revolutionary bone graft material and antimicrobial coatings for ... quarter and full year ended December 31, 2011: ... 72% to $9.1 million, compared to the $5.3 million for ...
Cached Biology Technology:All Global Partners With HealthEngage to Provide Unique Web 2.0 Patient Insights 2Elsevier Collaborates With Prophecy Healthcare to Enhance Its Staff Development Offerings for Healthcare Organizations 2Elsevier Collaborates With Prophecy Healthcare to Enhance Its Staff Development Offerings for Healthcare Organizations 3Elsevier Collaborates With Prophecy Healthcare to Enhance Its Staff Development Offerings for Healthcare Organizations 4Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 2Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 3Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 4Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 5Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 6Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 7Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 8Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 9Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 10
(Date:6/18/2013)... 18, 2013 The herbal extract of a yellow-flowered ... to increase the lifespan of fruit fly populations by ... researchers. , But it,s how Rhodiola ... that grabbed the attention of study leaders Mahtab Jafari ... works in a manner completely unrelated to dietary restriction ...
(Date:6/18/2013)... chemical modification of DNA and this modification can ... sequence. Until now, scientists believed that this epigenetic ... Today, a team of researchers from the University ... Louis-Jeantet Professor at the Faculty of Medicine, reveals ... that DNA methylation may play both a passive ...
(Date:6/18/2013)... that weight gain and increased head size in the first month ... early school age. , The study was led by University of ... children who were born full-term. , The results, published in the ... on 40% of their birthweight in the first four weeks had ... years of age, compared with babies who only put on 15% ...
Breaking Biology News(10 mins):Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds 2The secret of DNA methylation 2IQ link to baby's weight gain in first month 2
... at the University of California, San Francisco, have identified a ... parrots and exotic birds for more than 30 years. ... and Don Ganem, MD, also has developed a diagnostic test ... which will enable veterinarians worldwide to control the spread of ...
... treatments may sharpen mental performance in women with ... suggest that recharging a naturally occurring estrogen receptor ... The discovery suggests that drugs can be ... estrogen levels, as well as to protect against ...
... dioxide from the atmosphere, and from the human use of ... for the Earth,s life support system. The chemical balance of ... know that the pH of the sea,s surface water has ... beginning of industrialisation just over a century ago. Jon Havenhand ...
Cached Biology News:UCSF researchers identify virus behind mysterious parrot disease 2Improved estrogen reception may sharpen fuzzy memory 2Improved estrogen reception may sharpen fuzzy memory 3Acidification of the sea hampers reproduction of marine species 2
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
...
...
Biology Products: